Oncogenes play a key role in the development of various cancers, with PI3Ka being one of the most frequently mutated oncogenes across numerous cancer types. Mutations in PI3Ka occur in approximately 13% of all human cancers, with an even higher prevalence in breast cancer, affecting around 29% of cases. PI3KaH1047R is the most common mutation in PI3Ka.
The company we are profiling today is OnKure Therapeutics Inc. (OKUR), which is developing OKI-219, a novel therapeutic agent designed specifically to target the PI3Ka H1047R mutation.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com